Kyongbo Pharmaceutical was founded in 1987 with the explicit purpose of improving the health and the lives of humankind. Committed to developing active ingredients of the highest quality through innovations in manufacturing technology, Kyongbo Pharmaceutical became the first company in South Korea to develop the antibiotic Cefaclor. Our ongoing work to advance our own manufacturing and quality-management standards has even earned us the cGMP certifications from various authorities such as FDA in US, EDQM in Europe, PMDA in Japan, and CFDA in the China, giving us the license to manufacture active ingredients for sterile injectables and first generic drugs. Thanks to our continuing investments in facilities and R&D, we are exporting $85,000,000’s worth of products such as cephalosporin antibiotics, antihyperlipidemic agents, and anti-cancer drugs to more than thirty countries around the world and fast becoming a truly global corporation.

Since 2001 Kyongbo Pharmaceutical has manufactured various finished products including anesthetic, cardiovascular, digestive and antibiotic. Kyongbo Pharmaceutical is committed to evolving into a humanitarian corporation offering high-quality pharmaceuticals that improve the health and lives of humankind.